AU2016426350B2 — N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-cyclopropanecarboxamide dimethyl sulphoxide solvate as an MEK1/2 inhibitor
Assigned to R-Pharm Joint Stock Co (r-Pharm Jsc) · Expires 2020-08-27 · 6y expired
What this patent protects
The aim of the present invention is to create novel MEK1, MEK2 and MEK1/2 inhibitors which have lower toxicity in long-term dosage. This aim is achieved by the novel compound N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido…
USPTO Abstract
The aim of the present invention is to create novel MEK1, MEK2 and MEK1/2 inhibitors which have lower toxicity in long-term dosage. This aim is achieved by the novel compound N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-cyclopropanecarboxamide dimethyl sulphoxide solvate of formula 1.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.